In vivo gene editing therapies offer the potential to treat the root causes of many genetic
diseases. Realizing the promise of therapeutic in vivo gene editing requires the ability to …

Gene editing stands for the methods to precisely make changes to a specific nucleic acid
sequence. With the recent development of the clustered regularly interspaced short …

Over the past decades, great interest has been given to biomimetic nanoparticles (BNPs)
since the rise of targeted drug delivery systems and biomimetic nanotechnology. Biological …

The concept of using mRNA to produce its own medicine in situ in the body makes it an ideal
drug candidate, holding great potential to revolutionize the way we approach medicine. The …

A system for programmable export of RNA molecules from living cells would enable both
non-destructive monitoring of cell dynamics and engineering of cells capable of delivering …

Transient delivery of CRISPR‐based genome editing effectors is important to reduce off‐
target effects and immune responses. Recently extracellular vesicles (EVs) have been …

Therapeutic genome editing requires effective and targeted delivery methods. The delivery
of Cas9 mRNA using adeno-associated viruses has led to potent in vivo therapeutic efficacy …

Genome-editing technologies, such as CRISPR–Cas9, are promising for treating otherwise
incurable genetic diseases. Great progress has been made for ex vivo genome editing; …

Cell-type-specific in vivo delivery of genome editing molecules is the next breakthrough that
will drive biological discovery and transform the field of cell and gene therapy. Here, we …

Genetic diseases seriously threaten human health and have always been one of the
refractory conditions facing humanity. Currently, gene therapy drugs such as siRNA, shRNA …